Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company announced today the European Medicines Agency has accepted the filing of the marketing authorization application for once-daily oral teriflunomide for the treatment of MS.

Feed Date: 
February 23, 2012